Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 6/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24323711 | 0.81 | MEN1 (0.46) | MEN1KMT2AHPGDHTTPOLB | |
| SCHEMBL12312072 | 0.73 | MEN1 (0.54) | MEN1KMT2AHPGDHTTPOLB | |
| SCHEMBL12573346 | 0.73 | MEN1 (0.54) | MEN1KMT2AHPGDHTTPOLB | |
| SCHEMBL14368076 | 0.73 | MEN1 (0.59) | MEN1KMT2AHPGDHTTPOLB | |
| SCHEMBL8404634 | 0.73 | MEN1 (0.59) | MEN1KMT2AHPGDHTTPOLB | |
| SCHEMBL12880452 | 0.73 | MEN1 (0.59) | MEN1KMT2AHPGDHTTPOLB | |
| SCHEMBL14321957 | 0.72 | MEN1 (0.58) | MEN1KMT2AHPGDHTTPOLB | |
| SCHEMBL14322233 | 0.72 | MEN1 (0.58) | MEN1KMT2AHPGDHTTPOLB | |
| SCHEMBL14321958 | 0.72 | MEN1 (0.58) | MEN1KMT2AHPGDHTTPOLB | |
| SCHEMBL24322830 | 0.70 | ALDH1A1 (0.48) | MEN1KMT2AHPGDHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | MEN1 786/4885KMT2A 3149/4885HPGD 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.